Results 141 to 150 of about 235,104 (268)

Current trends in the treatment of hepatic encephalopathy

, 2009
Mohamad Rasm Al Sibae, Brendan M McGuireDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USAAbstract: Hepatic encephalopathy (HE) is a common reversible neuropsychiatric syndrome ...
Mohamad Rasm Al Sibae, Brendan M McGuire
core  

Minimal hepatic encephalopathy: Characteristics and comparison of the main diagnostic modalities

According to the latest clinical guidelines, minimal hepatic encephalopathy (MHE) is diagnosed by using a single test for which the center has experience and local norms. Nowadays, several tests are available.
Mariana P. Radicheva, Rumen V. Tenev, Nikola Mumdzhiev   +2 more
core   +1 more source

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

British Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien, Burabha Pussadhamma, Sirimas Kanjanawart, Thikhumporn Areesinpitak, Nontaya Nakkam, Chingching Foocharoen, Wichittra Tassaneeyakul, Suda Vannaprasaht   +7 more
wiley   +1 more source

Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to describe the pharmacokinetics (PK) of levetiracetam (LEV) in term neonates treated for neonatal seizures secondary to hypoxic–ischemic encephalopathy (HIE). Methods Fifteen neonates were included and received a loading dose ranging from 30 to 60 mg/kg followed by eight maintenance doses corresponding to one‐fourth of the loading
Léo Mimram, Moreno Ursino, Julie Leger, Emilie Bourrel‐Ponchel, Florence Flamein, Alexandra Chadie, Isabelle Guellec, Sarah Zohar, Vincent Jullien, Géraldine Favrais   +9 more
wiley   +1 more source

Carrion ecology: concepts, interdisciplinary synthesis, and perspectives

Biological Reviews, EarlyView.
ABSTRACT Carrion is a ubiquitous resource in both terrestrial and aquatic ecosystems, yet it has long been overlooked in ecological research. Over the past two decades, studies on carrion and the many organisms that exploit it have flourished, revealing not only wide‐ranging ecological functions but also significance far beyond ecology.
Marcos Moleón, José A. Sánchez‐Zapata, Travis L. DeVault, Wayne M. Getz, Zebensui Morales‐Reyes, Daniel Redondo‐Gómez, Lara Naves‐Alegre, Solange A. Batista‐Nunes, Esther Sebastián‐González, Juan M. Pérez‐García, Kelly A. Waters, Thijs van Overveld, Craig Smith, Nuria Selva, Thomas A. Schlacher, Graeme Ruxton, Jesús Rodríguez, Martina‐M. Quaggiotto, Paula L. Perrig, Norman Owen‐Smith, Thomas M. Newsome, Isabel Navas, Yoshihiro Nakashima, Ana Mateos, Carlos Martínez‐Carrasco, Daniel Martín‐Vega, Berta Martín‐López, Antoni Margalida, Sergio A. Lambertucci, Adam Kane, Kevin Healy, Akane Hashizume, Antonio J. García‐Fernández, José A. Donázar, M. Eric Benbow, James C. Beasley, Philip S. Barton, Kathleen A. Alexander, Eneko Arrondo   +38 more
wiley   +1 more source

Alzheimer II cells, encephalopathy

, 1997
Alzheimer II cells, encephalopathy. Hepatic encephalopathy.

core  

GRIA2 Variant Associated With Paradoxical Response to Perampanel Expanding the Spectrum of GRIA2‐Related Epileptic Encephalopathy: Case Report and Literature Review

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction GRIA2 encodes the GluA2 ionotropic α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor subunit. Pathogenic GRIA2 variants cause epilepsy, developmental delay, and neurobehavioral disorders. Characterizations of clinical features, including seizure types and their treatments, in patients with GRIA2‐related ...
Sai Srihitha Dommata, Chhitij Tiwari, Zheng Fan, Muge Gucsavas‐Calikoglu, Yael Shiloh‐Malawsky, Kimberly S. Foss, Stephanie N. Peck, Erin L. Heinzen, Chon Lee, Senyene E. Hunter   +9 more
wiley   +1 more source

Opsoclonus in Pediatric Patients: Differential Diagnosis and a Practical Approach to Evaluation

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Opsoclonus is an ocular dyskinesia characterized by involuntary, arrhythmic, multidirectional saccades. In pediatrics, opsoclonus is most commonly attributed to the rare neuroinflammatory disorder opsoclonus‐myoclonus‐ataxia syndrome (OMAS), typically considered a paraneoplastic syndrome associated with neural crest tumors. However, opsoclonus
Aubrey C. Reed, Supreet S. Randhawa, Jason H. Peragallo, Prabhumallikarjun Patil, Grace Gombolay, Varun Kannan   +5 more
wiley   +1 more source

Effect of Jian-Pi-Zhi-Dong Decoction on striatal glutamate and γ-aminobutyric acid levels detected using microdialysis in a rat model of Tourette syndrome

Neuropsychiatric Disease and Treatment, 2016
Wen Zhang,1,* Li Wei,2,* Wenjing Yu,1 Xia Cui,1 Xiaofang Liu,2 Qian Wang,1 Sumei Wang2 1Department of Pediatrics, The Third Affiliated Hospital, 2Department of Pediatrics, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People& ...
Zhang W, Wei L, Yu W, Cui X, Liu X, Wang Q, Wang S   +6 more
doaj  

A Practical Guide to Implementing Real‐World Evidence as Primary Basis for Approval and Label Expansion

Clinical Pharmacology &Therapeutics, EarlyView.
In June 2026, the FDA issued a revised draft guidance describing the circumstances in which one adequate and well‐controlled clinical investigation plus confirmatory evidence may satisfy the statutory substantial evidence standard for establishing efficacy and safety. Confirmatory evidence includes real‐world evidence (RWE).
Tracy J. Mayne, Maurice A. Brookhart, Nancy A. Dreyer   +2 more
wiley   +1 more source